J.Jill, Inc. (JILL) formed double bottom with $6.46 target or 9.00% below today’s $7.10 share price. J.Jill, Inc. (JILL) has $310.61M valuation. The stock increased 10.08% or $0.65 during the last trading session, reaching $7.1. About 355,556 shares traded. J.Jill, Inc. (NYSE:JILL) has 0.00% since December 5, 2016 and is . It has underperformed by 16.70% the S&P500.
Veracyte, Inc. operates as a molecular diagnostics firm in the United States. The company has market cap of $225.00 million. The firm uses genomic technology to resolve diagnostic ambiguity. It currently has negative earnings. It offers Afirma Thyroid FNA Analysis solution for use in thyroid cancer diagnosis; cytopathology testing services; and the Afirma Malignancy Classifiers to manage thyroid nodule patients.
Among 10 analysts covering J. Jill (NYSE:JILL), 6 have Buy rating, 0 Sell and 4 Hold. Therefore 60% are positive. J. Jill had 17 analyst reports since April 3, 2017 according to SRatingsIntel. The stock has “Overweight” rating by Morgan Stanley on Monday, April 3. The firm earned “Buy” rating on Thursday, October 12 by Jefferies. The firm earned “Buy” rating on Monday, April 3 by Deutsche Bank. The stock has “Market Perform” rating by Wells Fargo on Monday, April 3. RBC Capital Markets initiated J.Jill, Inc. (NYSE:JILL) rating on Monday, April 3. RBC Capital Markets has “Outperform” rating and $16 target. As per Monday, April 3, the company rating was initiated by Suntrust Robinson. As per Monday, June 19, the company rating was maintained by Jefferies. Bank of America initiated the shares of JILL in report on Monday, April 3 with “Buy” rating. Macquarie Research initiated it with “Neutral” rating and $14 target in Monday, April 3 report. The rating was maintained by RBC Capital Markets on Wednesday, August 16 with “Buy”.
The stock decreased 0.30% or $0.02 during the last trading session, reaching $6.61. About 10,312 shares traded. Veracyte, Inc. (VCYT) has risen 56.46% since December 5, 2016 and is uptrending. It has outperformed by 39.76% the S&P500.
Acuta Capital Partners Llc holds 7.18% of its portfolio in Veracyte, Inc. for 3.08 million shares. Cannell Capital Llc owns 1.66 million shares or 3.96% of their US portfolio. Moreover, First Light Asset Management Llc has 2.11% invested in the company for 754,560 shares. The New York-based Broadfin Capital Llc has invested 1.46% in the stock. Eventide Asset Management Llc, a Massachusetts-based fund reported 2.13 million shares.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.